Revolution Medicines Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
412 / 1361
Position in country
7134 / 14179
Return on Assets, %
-37.6
-40.3
Net income margin, %
-21770.5
-180
EBITDA margin, %
-24038.9
-168.2
Debt to Equity, %
0
3.2
Intangible assets and goodwill, %
3.5
0.2
Revenue CAGR 3Y, %
-35.5
12.5
Total Equity change 1Y, %
166.5
-9
Revenue Y, % chg
-67.3
0
P/BV
3.2
1.8
P/S
512.9
10.3
EV/S
352.9
7.5
EV/EBITDA
-2.7
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
13.6
131.1
Expected dividend per share
0
0
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Revolution Medicines Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
5940.3
Ticker
RVMD.O
ISIN
US76155X1000
IPO date
2020-02-13
Availability on Russian exchanges
Yes
Reporting for
2024-02-26
Date fact. publication of reports
2023-12-31
Company Description
Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: